COLL
NASDAQCollegium Pharmaceutical Inc.
Price$30.70+0.22 (+0.72%)
01:30 PM06:30 PM
News · 26 weeks57+300%
2025-12-072026-05-31
Mix3690d
- Insider15(42%)
- SEC Filings10(28%)
- Other7(19%)
- Earnings3(8%)
- M&A1(3%)
Latest news
25 items- SECSEC Form S-8 filed by Collegium Pharmaceutical Inc.S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- SECSEC Form S-8 filed by Collegium Pharmaceutical Inc.S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- PRCollegium to Participate in 2026 Jefferies Global Healthcare ConferenceSTOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. Details of the event are as follows: Fireside Chat Date and Time: Wednesday, June 3, 2026, at 1:20 p.m. ETNew York, NY A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharmaceutical, Inc.Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering
- INSIDERDirector Freund John Gordon sold $681 worth of shares (20 units at $34.05), decreasing direct ownership by 0.02% to 83,952 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Bohlin Garen G was granted 8,741 shares, increasing direct ownership by 14% to 71,000 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Freund John Gordon was granted 8,741 shares, exercised 8,700 shares at a strike of $16.49 and sold $142,547 worth of shares (4,127 units at $34.54), increasing direct ownership by 19% to 83,972 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Paya Carlos V was granted 8,741 shares, increasing direct ownership by 45% to 28,323 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Lurker Nancy was granted 8,741 shares, increasing direct ownership by 49% to 26,758 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Balice-Gordon Rita J. was granted 8,741 shares, increasing direct ownership by 17% to 61,370 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Glancy Donovan Michael was granted 17,482 shares (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Santini Gino was granted 8,741 shares, increasing direct ownership by 9% to 103,783 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERSEC Form 3 filed by new insider Glancy Donovan Michael3 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- SECCollegium Pharmaceutical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- INSIDERDirector Lurker Nancy sold $161,861 worth of shares (4,500 units at $35.97), decreasing direct ownership by 20% to 18,017 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
- INSIDERDirector Bohlin Garen G exercised 8,700 shares at a strike of $16.49 and sold $323,491 worth of shares (8,700 units at $37.18) (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- SECCollegium Pharmaceutical Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- PRCollegium Completes Acquisition of AZSTARYS® from Corium Therapeutics– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – – Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition – – 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million – STOUGHTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), today announced that it has completed the acquisition of AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a cent
- SECSEC Form 144 filed by Collegium Pharmaceutical Inc.144 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
- SECSEC Form SCHEDULE 13G filed by Collegium Pharmaceutical Inc.SCHEDULE 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
- SECSEC Form 10-Q filed by Collegium Pharmaceutical Inc.10-Q - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- SECCollegium Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- PRCollegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year – – Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million – – Reaffirmed Full-Year 2026 Guidance for the Current Business – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., May 07
- PRCollegium to Report First Quarter 2026 Financial Results on May 7, 2026STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2026 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Comp
COLL FAQ
7 questionsWhat does Collegium Pharmaceutical Inc. do?
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003...Where does COLL stock trade?
Collegium Pharmaceutical Inc. (COLL) is listed on NASDAQ.What sector and industry is COLL in?
Collegium Pharmaceutical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Collegium Pharmaceutical Inc. go public?
Collegium Pharmaceutical Inc. (COLL) completed its IPO in 2015.What are analysts saying about COLL?
Collegium Pharmaceutical Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2025-12-09. Recent price targets range from $3600.00 to $4700.00.What companies are similar to COLL?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare COLL side-by-side with any of them on Quantisnow.How can I track COLL on Quantisnow?
Quantisnow aggregates Collegium Pharmaceutical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COLL to receive live email and push alerts on every new disclosure.